MX2019011717A - Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos. - Google Patents

Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.

Info

Publication number
MX2019011717A
MX2019011717A MX2019011717A MX2019011717A MX2019011717A MX 2019011717 A MX2019011717 A MX 2019011717A MX 2019011717 A MX2019011717 A MX 2019011717A MX 2019011717 A MX2019011717 A MX 2019011717A MX 2019011717 A MX2019011717 A MX 2019011717A
Authority
MX
Mexico
Prior art keywords
beta
alpha
cscs
compositions
methods
Prior art date
Application number
MX2019011717A
Other languages
English (en)
Spanish (es)
Inventor
Cheresh David
Wettersten Hiromi
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2019011717A publication Critical patent/MX2019011717A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019011717A 2017-03-31 2018-03-30 Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos. MX2019011717A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479768P 2017-03-31 2017-03-31
PCT/US2018/025470 WO2018183894A1 (en) 2017-03-31 2018-03-30 Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers

Publications (1)

Publication Number Publication Date
MX2019011717A true MX2019011717A (es) 2019-12-16

Family

ID=63676868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011717A MX2019011717A (es) 2017-03-31 2018-03-30 Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.

Country Status (12)

Country Link
US (2) US20200109205A1 (enExample)
EP (2) EP4353318A3 (enExample)
JP (2) JP2020512978A (enExample)
KR (1) KR102630070B1 (enExample)
CN (1) CN110662559A (enExample)
AU (1) AU2018243670B2 (enExample)
BR (1) BR112019020451A2 (enExample)
CA (1) CA3058458A1 (enExample)
EA (1) EA201992326A1 (enExample)
IL (1) IL269746A (enExample)
MX (1) MX2019011717A (enExample)
WO (1) WO2018183894A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12383634B2 (en) 2019-07-24 2025-08-12 Korea Basic Science Institute Single domain antibody targeting αVβ3 integrin
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers
MX2022013207A (es) * 2020-04-23 2023-01-24 Alpha Beta Holdings Llc Metodos y composiciones para el tratamiento de cancer.
CN112626118B (zh) * 2020-11-12 2023-06-23 清华-伯克利深圳学院筹备办公室 细胞株及其应用
CN118284622A (zh) * 2021-09-30 2024-07-02 阿尔法贝塔控股有限责任公司 治疗癌症的组合物和方法
CN115960160B (zh) * 2021-10-12 2024-07-16 南京大学 活细胞膜整合素αvβ3聚糖的原位糖链延长方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
RU2194528C2 (ru) * 1996-05-31 2002-12-20 Дзе Скриппс Рисерч Инститьют Способы и композиции, используемые для ингибирования ангиогенеза
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CN1261791A (zh) 1997-07-02 2000-08-02 Sdg有限公司 诊断或治疗用途的靶向脂质体构建物
KR100704140B1 (ko) 1999-02-12 2007-04-09 더 스크립스 리서치 인스티튜트 혈관형성 억제제 및 항-종양 면역요법제를 포함하는, 종양 및 전이를 치료하기 위한 약제학적 조성물 및 이를 포함하는 키트
CN1561968A (zh) 1999-04-23 2005-01-12 三菱化学株式会社 与抗体和聚亚烷基二醇结合的脂质体
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7858117B2 (en) 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
US20040001835A1 (en) * 2002-03-04 2004-01-01 Medimmune, Inc. Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
CN1917859A (zh) 2003-12-24 2007-02-21 日本株式会社Ltt生物医药 载药纳米微粒及其制备方法以及含有该纳米微粒的非肠道给药用制剂
WO2005084710A2 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
WO2006014035A1 (en) 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
US20060040325A1 (en) * 2004-08-16 2006-02-23 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
SG163548A1 (en) * 2005-06-30 2010-08-30 Centocor Inc Methods and compositions with enhanced therapeutic activity
WO2007012191A1 (en) 2005-07-27 2007-02-01 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
US20080088046A1 (en) 2006-10-13 2008-04-17 Steffen Panzner Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
EP1959958A4 (en) * 2005-11-14 2010-07-14 Univ Southern California INTEGRIN-BINDING SMALL MOLECULES
US20080089928A1 (en) 2006-06-13 2008-04-17 Stavroula Sofou Liposome drug carriers with ph-sensitivity
US20110319335A1 (en) * 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
US20140154264A1 (en) * 2011-06-02 2014-06-05 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
AU2014331118B2 (en) * 2013-10-01 2019-07-25 Medimmune Limited Methods of treating and diagnosing alpha-V-beta-6 overexpressing cancer
US20160280787A1 (en) * 2013-11-11 2016-09-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
US11052089B2 (en) * 2014-12-18 2021-07-06 The Regents Of The University Of California Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers

Also Published As

Publication number Publication date
EP4353318A3 (en) 2024-07-17
BR112019020451A2 (pt) 2020-04-28
JP2020512978A (ja) 2020-04-30
US20200109205A1 (en) 2020-04-09
CA3058458A1 (en) 2018-10-04
KR20190133205A (ko) 2019-12-02
US20240067733A1 (en) 2024-02-29
AU2018243670B2 (en) 2025-05-01
EA201992326A1 (ru) 2020-03-13
IL269746A (en) 2019-11-28
EP3600422A1 (en) 2020-02-05
JP2021095423A (ja) 2021-06-24
EP3600422A4 (en) 2021-01-13
AU2018243670A1 (en) 2019-10-31
WO2018183894A1 (en) 2018-10-04
KR102630070B1 (ko) 2024-01-26
EP3600422B1 (en) 2023-10-18
CN110662559A (zh) 2020-01-07
EP4353318A2 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
MX2019011717A (es) Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.
ZA202203511B (en) Disrupting tumor tissues by targeting fibroblast activation protein (fap)
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
MX2024013525A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
WO2018236870A3 (en) METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS WITH A CHIMERIC ANTIGENIC RECEPTOR
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
PH12021552831A1 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
PH12022550509A1 (en) Anti-cd73 antibodies
PE20211786A1 (es) Anticuerpos humanizados contra c-kit
ZA202405748B (en) Universal abt compounds and uses thereof
EP4233909A3 (en) Anti-cmet antibody drug conjugates and methods for their use
MX2018014950A (es) Terapia de combinacion.
MX378807B (es) Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
SG178930A1 (en) Therapeutic dll4 binding proteins
MX2018011035A (es) Anticuerpos-anti-mica.
MY192146A (en) Binding molecules specific for asct2 and uses thereof
MX2018014863A (es) Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3.
WO2019112347A3 (ko) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
MX2020008613A (es) Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.
MX2020005473A (es) Anticuerpos humanizados que se dirigen al factor tisular humano.
WO2018213064A8 (en) Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
MX2017011600A (es) Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
WO2017062615A3 (en) Combination therapy for the treatment of cancer
WO2023018722A3 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8